This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Epizyme Crecimiento futuro
Future controles de criterios 2/6
Información clave
15.8%
Tasa de crecimiento de los beneficios
16.6%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 28.4% |
| Tasa de crecimiento de los ingresos | 37.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16
Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16
Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2024 | 136 | -173 | N/A | N/A | 3 |
| 12/31/2023 | 80 | -196 | N/A | N/A | 4 |
| 12/31/2022 | 49 | -182 | N/A | N/A | 4 |
| 6/30/2022 | 53 | -208 | -209 | -209 | N/A |
| 3/31/2022 | 38 | -236 | -211 | -210 | N/A |
| 12/31/2021 | 37 | -251 | -227 | -227 | N/A |
| 9/30/2021 | 34 | -267 | -229 | -228 | N/A |
| 6/30/2021 | 33 | -257 | -229 | -228 | N/A |
| 3/31/2021 | 22 | -251 | -250 | -224 | N/A |
| 12/31/2020 | 16 | -232 | -257 | -206 | N/A |
| 9/30/2020 | 12 | -222 | -239 | -189 | N/A |
| 6/30/2020 | 14 | -202 | -235 | -184 | N/A |
| 3/31/2020 | 17 | -192 | -200 | -174 | N/A |
| 12/31/2019 | 24 | -173 | -148 | -147 | N/A |
| 9/30/2019 | 29 | -140 | -135 | -134 | N/A |
| 6/30/2019 | 23 | -141 | -132 | -132 | N/A |
| 3/31/2019 | 30 | -122 | -123 | -123 | N/A |
| 12/31/2018 | 22 | -124 | -122 | -122 | N/A |
| 9/30/2018 | 12 | -137 | -130 | -129 | N/A |
| 6/30/2018 | 12 | -137 | -133 | -133 | N/A |
| 3/31/2018 | 10 | -136 | -119 | -118 | N/A |
| 12/31/2017 | 10 | -134 | -121 | -120 | N/A |
| 9/30/2017 | 10 | -133 | -112 | -111 | N/A |
| 6/30/2017 | 17 | -120 | -98 | -97 | N/A |
| 3/31/2017 | 8 | -120 | -105 | -104 | N/A |
| 12/31/2016 | 8 | -110 | -97 | -96 | N/A |
| 9/30/2016 | 8 | -97 | -97 | -97 | N/A |
| 6/30/2016 | 2 | -96 | -80 | -79 | N/A |
| 3/31/2016 | 2 | -94 | N/A | -76 | N/A |
| 12/31/2015 | 3 | -132 | N/A | -73 | N/A |
| 9/30/2015 | 12 | -125 | N/A | -72 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: EPZM is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: EPZM is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: EPZM is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: EPZM's revenue (37.6% per year) is forecast to grow faster than the US market (7.9% per year).
Ingresos de alto crecimiento: EPZM's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if EPZM's Return on Equity is forecast to be high in 3 years time